Reports Q1 revenue $255.7M, consensus $248.13M. “The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos. We believe this is just the beginning as more and more healthcare providers and life science companies embrace AI.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- tempus AI Inc Class A call volume above normal and directionally bullish
- Unusually active option classes on open May 6th
- Tempus AI, Inc. Class A (TEM) Q1 Earnings Cheat Sheet
- Tempus AI publishes xF+ assay study results in Journal of Molecular Diagnostics
- Analysts Split on High-Stakes ‘Call Option’ for Tempus AI Stock (TEM)